| Ranked [title] Word list | Historiographs | Help Glossary HistCite Guide About |
|
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James C, Ugo V, Le Couedic JP, Staerk J, et al. NATURE 434 (7037): 1144-1148, APR 28 2005 and the citing papers |
| Nodes: 181, Authors: 753, Journals: 66, Cited References: 5591, Words: 617
Yearly output | Document Type | Language | Institution | Institution with Subdivision | Country |
| View: Overview | Sorted by number of publications (Pubs). |
| # | Word | Pubs | TLCS | TGCS |
|---|---|---|---|---|
| 1 | JAK | 71 | 485 | 538 |
| 2 | MUTATION | 65 | 514 | 576 |
| 3 | MYELOPROLIFERATIVE | 47 | 153 | 185 |
| 4 | V617F | 45 | 210 | 250 |
| 5 | DISORDERS | 44 | 155 | 189 |
| 6 | VERA | 29 | 277 | 291 |
| 7 | CHRONIC | 26 | 98 | 122 |
| 8 | POLYCYTHEMIA | 25 | 81 | 87 |
| 9 | ESSENTIAL | 23 | 71 | 91 |
| 10 | MYELOFIBROSIS | 21 | 31 | 37 |
| 11 | THROMBOCYTHEMIA | 19 | 32 | 40 |
| 12 | MYELOID | 17 | 52 | 86 |
| 13 | PATIENTS | 17 | 32 | 36 |
| 14 | CLINICAL | 14 | 59 | 80 |
| 15 | KINASE | 13 | 42 | 56 |
| 16 | LEUKEMIA | 13 | 51 | 66 |
| 17 | ANALYSIS | 12 | 18 | 21 |
| 18 | TYROSINE | 12 | 43 | 111 |
| 19 | MOLECULAR | 11 | 21 | 28 |
| 20 | IDIOPATHIC | 10 | 8 | 8 |
| 21 | ACTIVATION | 9 | 27 | 31 |
| 22 | ACUTE | 9 | 49 | 68 |
| 23 | ASSOCIATED | 9 | 10 | 12 |
| 24 | DIAGNOSIS | 9 | 19 | 28 |
| 25 | METAPLASIA | 9 | 17 | 23 |
| 26 | ERYTHROPOIETIN | 8 | 0 | 5 |
| 27 | IMPLICATIONS | 8 | 39 | 60 |
| 28 | PATHOGENESIS | 8 | 14 | 17 |
| 29 | STAT | 8 | 2 | 3 |
| 30 | THROMBOSIS | 8 | 8 | 9 |
| # | Word | Pubs | TLCS | TGCS |
| 31 | ACTIVATING | 7 | 19 | 25 |
| 32 | BONE | 7 | 7 | 8 |
| 33 | EXPRESSION | 7 | 37 | 40 |
| 34 | MARROW | 7 | 7 | 8 |
| 35 | ACQUIRED | 6 | 57 | 67 |
| 36 | CANCER | 6 | 3 | 56 |
| 37 | CELLS | 6 | 7 | 7 |
| 38 | FEATURES | 6 | 7 | 7 |
| 39 | JAK2V617F | 6 | 48 | 58 |
| 40 | KINASES | 6 | 13 | 73 |
| 41 | MALIGNANCIES | 6 | 12 | 31 |
| 42 | PLATELET | 6 | 3 | 8 |
| 43 | POLYCYTHAEMIA | 6 | 213 | 223 |
| 44 | STATUS | 6 | 42 | 56 |
| 45 | TREATMENT | 6 | 2 | 4 |
| 46 | CLONAL | 5 | 182 | 182 |
| 47 | DETECTION | 5 | 7 | 8 |
| 48 | DISEASE | 5 | 21 | 32 |
| 49 | ERYTHROID | 5 | 9 | 11 |
| 50 | FORMATION | 5 | 25 | 28 |
| 51 | GENE | 5 | 15 | 25 |
| 52 | HUMAN | 5 | 0 | 4 |
| 53 | JANUS | 5 | 12 | 18 |
| 54 | MANAGEMENT | 5 | 1 | 2 |
| 55 | MUTATIONS | 5 | 5 | 7 |
| 56 | NEW | 5 | 4 | 7 |
| 57 | ROLE | 5 | 3 | 3 |
| 58 | SIGNAL | 5 | 2 | 4 |
| 59 | THERAPY | 5 | 3 | 54 |
| 60 | UNCOMMON | 5 | 13 | 14 |
| # | Word | Pubs | TLCS | TGCS |
| 61 | BASIS | 4 | 10 | 12 |
| 62 | BUDD-CHIARI | 4 | 0 | 1 |
| 63 | CLASSIFICATION | 4 | 19 | 29 |
| 64 | COLONY | 4 | 2 | 2 |
| 65 | CONSTITUTIVE | 4 | 184 | 184 |
| 66 | DEVELOPMENT | 4 | 0 | 0 |
| 67 | DISEASES | 4 | 1 | 1 |
| 68 | IDENTIFICATION | 4 | 57 | 61 |
| 69 | INSIGHTS | 4 | 3 | 3 |
| 70 | MYELOMONOCYTIC | 4 | 22 | 30 |
| 71 | PCM1-JAK | 4 | 8 | 13 |
| 72 | PRV | 4 | 38 | 43 |
| 73 | RECEPTOR | 4 | 26 | 30 |
| 74 | SIGNALING | 4 | 10 | 19 |
| 75 | SYNDROME | 4 | 0 | 1 |
| 76 | THERAPEUTIC | 4 | 11 | 12 |
| 77 | TRANSLOCATION | 4 | 8 | 13 |
| 78 | BIOPSIES | 3 | 3 | 4 |
| 79 | BLEEDING | 3 | 5 | 5 |
| 80 | CAUSES | 3 | 184 | 184 |
| 81 | CELL | 3 | 8 | 13 |
| 82 | CLASSIC | 3 | 11 | 12 |
| 83 | CONTROL | 3 | 9 | 13 |
| 84 | CORRELATION | 3 | 3 | 3 |
| 85 | CURRENT | 3 | 6 | 8 |
| 86 | DIAGNOSTIC | 3 | 4 | 5 |
| 87 | DOMAIN | 3 | 2 | 2 |
| 88 | ERYTHROCYTOSIS | 3 | 4 | 5 |
| 89 | FACTOR | 3 | 0 | 3 |
| 90 | FACTORS | 3 | 2 | 2 |
| # | Word | Pubs | TLCS | TGCS |
| 91 | FUNCTION | 3 | 8 | 8 |
| 92 | GENETIC | 3 | 0 | 1 |
| 93 | HEMATOLOGIC | 3 | 0 | 6 |
| 94 | HEMATOLOGICAL | 3 | 1 | 2 |
| 95 | HEMATOPOIETIC | 3 | 2 | 2 |
| 96 | INCREASED | 3 | 4 | 5 |
| 97 | LEADING | 3 | 180 | 180 |
| 98 | LEUKAEMIA | 3 | 7 | 11 |
| 99 | LEUKEMIAS | 3 | 27 | 37 |
| 100 | LONG-TERM | 3 | 23 | 27 |
| 101 | LYMPHOMA | 3 | 1 | 2 |
| 102 | NOVEL | 3 | 0 | 1 |
| 103 | PHOSPHORYLATION | 3 | 0 | 4 |
| 104 | PRESENCE | 3 | 0 | 2 |
| 105 | RESPONSE | 3 | 1 | 2 |
| 106 | RISK | 3 | 0 | 1 |
| 107 | SECONDARY | 3 | 15 | 18 |
| 108 | SIGNALLING | 3 | 180 | 180 |
| 109 | STEM | 3 | 2 | 3 |
| 110 | THROMBOCYTHAEMIA | 3 | 39 | 51 |
| 111 | THROMBOPOIETIN | 3 | 7 | 11 |
| 112 | TRANSCRIPTION | 3 | 1 | 2 |
| 113 | TRANSDUCTION | 3 | 2 | 4 |
| 114 | TREPHINE | 3 | 3 | 4 |
| 115 | ABL-NEGATIVE | 2 | 2 | 3 |
| 116 | ABSENCE | 2 | 0 | 0 |
| 117 | ACTIVATED | 2 | 0 | 0 |
| 118 | ADVANCES | 2 | 6 | 8 |
| 119 | ALPHA | 2 | 1 | 2 |
| 120 | APPLICATIONS | 2 | 0 | 1 |
| # | Word | Pubs | TLCS | TGCS |
| 121 | ASSAYS | 2 | 0 | 0 |
| 122 | ASSOCIATION | 2 | 2 | 7 |
| 123 | ATYPICAL | 2 | 4 | 7 |
| 124 | B-CELL | 2 | 0 | 0 |
| 125 | BCR | 2 | 2 | 3 |
| 126 | BIOLOGY | 2 | 0 | 1 |
| 127 | CANCERS | 2 | 8 | 8 |
| 128 | CARRYING | 2 | 0 | 0 |
| 129 | CHROMOSOME-NEGATIVE | 2 | 23 | 28 |
| 130 | CLASSICAL | 2 | 1 | 2 |
| 131 | CLINICOPATHOLOGIC | 2 | 0 | 0 |
| 132 | CLINICOPATHOLOGICAL | 2 | 0 | 1 |
| 133 | CML | 2 | 23 | 29 |
| 134 | COEXPRESSION | 2 | 2 | 2 |
| 135 | COMPLICATIONS | 2 | 3 | 3 |
| 136 | CORRELATES | 2 | 23 | 27 |
| 137 | CRITERIA | 2 | 0 | 1 |
| 138 | CURVE | 2 | 2 | 2 |
| 139 | DERIVED | 2 | 3 | 3 |
| 140 | DIFFERENT | 2 | 2 | 2 |
| 141 | DROSOPHILA | 2 | 1 | 1 |
| 142 | ENDOGENOUS | 2 | 2 | 2 |
| 143 | ETIOLOGY | 2 | 3 | 3 |
| 144 | EXPANSION | 2 | 0 | 0 |
| 145 | FAMILIAL | 2 | 6 | 7 |
| 146 | FLT | 2 | 0 | 1 |
| 147 | FUSION | 2 | 8 | 13 |
| 148 | GATA | 2 | 3 | 6 |
| 149 | GENES | 2 | 1 | 1 |
| 150 | GROWTH | 2 | 0 | 2 |
| # | Word | Pubs | TLCS | TGCS |
| 151 | HAEMATOLOGICAL | 2 | 0 | 1 |
| 152 | HEMATOPOIESIS | 2 | 2 | 2 |
| 153 | HODGKIN | 2 | 1 | 2 |
| 154 | HOMOZYGOUS | 2 | 0 | 5 |
| 155 | HYDROXYUREA | 2 | 0 | 1 |
| 156 | IDENTIFIES | 2 | 2 | 2 |
| 157 | IMATINIB | 2 | 1 | 3 |
| 158 | INCIDENCE | 2 | 0 | 0 |
| 159 | INFLUENCE | 2 | 0 | 0 |
| 160 | LEVELS | 2 | 0 | 0 |
| 161 | LIGHTCYCLER | 2 | 1 | 1 |
| 162 | LOSS | 2 | 8 | 8 |
| 163 | MECHANISMS | 2 | 4 | 8 |
| 164 | MEGAKARYOCYTIC | 2 | 23 | 28 |
| 165 | MELTING | 2 | 2 | 2 |
| 166 | MOUSE | 2 | 0 | 0 |
| 167 | MPD | 2 | 27 | 30 |
| 168 | MUTATIONAL | 2 | 3 | 3 |
| 169 | MYB | 2 | 0 | 0 |
| 170 | NEUTROPHILIC | 2 | 2 | 2 |
| 171 | NOVO | 2 | 5 | 5 |
| 172 | OCCURRENCE | 2 | 48 | 56 |
| 173 | OCCURS | 2 | 19 | 25 |
| 174 | OVEREXPRESSION | 2 | 25 | 28 |
| 175 | PATHOLOGICAL | 2 | 4 | 4 |
| 176 | PERSPECTIVES | 2 | 0 | 0 |
| 177 | PHILADELPHIA | 2 | 23 | 28 |
| 178 | PLATELETS | 2 | 0 | 0 |
| 179 | POINT | 2 | 0 | 0 |
| 180 | PRIMARY | 2 | 1 | 1 |
| # | Word | Pubs | TLCS | TGCS |
| 181 | PROGNOSTIC | 2 | 23 | 27 |
| 182 | PROSPECTIVE | 2 | 18 | 25 |
| 183 | PROTEIN | 2 | 0 | 5 |
| 184 | QUANTITATIVE | 2 | 3 | 3 |
| 185 | RARE | 2 | 24 | 29 |
| 186 | RELATION | 2 | 22 | 29 |
| 187 | RELEVANCE | 2 | 21 | 25 |
| 188 | REPORT | 2 | 18 | 25 |
| 189 | RESEARCH | 2 | 1 | 1 |
| 190 | RESISTANCE | 2 | 1 | 2 |
| 191 | SCIENTIFIC | 2 | 14 | 16 |
| 192 | SCREENING | 2 | 15 | 17 |
| 193 | SERIES | 2 | 1 | 1 |
| 194 | SERUM | 2 | 0 | 0 |
| 195 | SINGLE | 2 | 2 | 2 |
| 196 | SPONTANEOUS | 2 | 0 | 0 |
| 197 | TARGETING | 2 | 0 | 6 |
| 198 | TARGETS | 2 | 3 | 54 |
| 199 | TEST | 2 | 6 | 7 |
| 200 | THROMBOCYTOSIS | 2 | 0 | 0 |